Abstracts tagged "secukinumab"

Abstract Number: 0908 • ACR Convergence 2021
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
Uta Kiltz¹, Xenofon Baraliakos¹, Jan Brandt-Jrgens², Ulf Wagner³, Sebastian Lieb⁴, Christian Sieder⁵, Christian Mann⁵ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Universitätsklinikum Leipzig, Leipzig, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory back pain in patients (pts) with ankylosing spondylitis (AS). However, an increased risk of side…
Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Annika Boas⁶ and Hans-Peter Tony⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Abstract Number: 1832 • ACR Convergence 2021
Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
Soraia Azevedo¹, Jose Tavares-Costa², Pedro Laires³, Salomé Garcia⁴, Patricia Nero⁵, Jorge Pestana⁶, Joana Martins-Martinho⁷, Ana Bento Silva⁸, Joana Rodrigues⁹, Graca Sequeira¹⁰, Emanuel Costa¹¹, Filipe Cunha Santos¹², Carolina Furtado¹³, Bernardo Santos¹⁴, Ana Raposo¹⁵, Liliana Saraiva¹⁶, Beatriz Samões¹⁷, Filipe Barcelos¹⁸, Maria José Santos⁶ and Helena Santos¹⁹, ¹Unidade Local de Saude do Alto Minho, Ponte de lima, Portugal, ²Rheumatology Department - Unidade Local de Saude do Alto Minho, Ponte de Lima, Portugal, ³Novartis Portugal / ENSP – NOVA University of Lisbon, Lisbon, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁵CUF, TELHEIRAS, Portugal, ⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ⁷Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ⁸Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁹Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹¹Hospital de Braga, Braga, Portugal, ¹²Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹³Rheumatology Department, Hospital do Divino Espírito Santo de Ponta Delgada, Ponta Delgada, Portugal, ¹⁴Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁵Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ¹⁶Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹⁷Rheumatology Department, Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal, ¹⁸Instituto Português de Reumatologia, Lisbon, Portugal, ¹⁹Portuguese Institute of Rheumatology, Lisbon, Portugal
Background/Purpose: Secukinumab has demonstrated to be efficacious for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS): PASI, ACR and ASAS magnitudes of response have generally…
Abstract Number: 934 • 2019 ACR/ARP Annual Meeting
Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of 556 Spondylarthritis
Benoit Flachaire¹, Jean-Guillaume Letarouilly ², Céline Labadie ³, Nicolas Cohen ⁴, Vincent Pradel ⁵, Jérémie Sellam ⁶, Pascal Richette ⁷, Philippe Dieudé ⁸, Pascal Claudepierre ⁹, Bruno Fautrel ¹⁰, Eric Houvenagel ¹¹, Chi Duc Nguyen ¹², Marie-Hélène Guyot ¹³, Nicolas Segaud ¹⁴, Frédéric Maury ¹⁵, Laurent Marguerie ¹⁶, Xavier Deprez ¹⁷, Jean-Hugues Salmon ¹⁸, Guy Baudens ¹⁹, Elisabeth Gervais ²⁰, Corinne Miceli-Richard ²¹, Isabelle Chary-Valckenaere ²², Pierre Lafforgue ²³, Damien Loeuille ²⁴, Christophe Richez ²⁵, René-Marc Flipo ²⁶ and Thao Pham ²³, ¹Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, ²University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, ³Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, ⁴APHM -Assistance publique des hôpitaux de Marseille, Marseille, France, ⁵APHM -Assistance publique des hôpitaux de Marseille, Marseille, Finland, ⁶Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ⁸Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ⁹Rheumatology, CHU Henri Mondor Créteil, Paris, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ¹¹Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, ¹²Rheumatology, Hospital of Béthune, Béthune, Béthune, France, ¹³Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, ¹⁴Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, ¹⁵Rheumatology, Private Practice, Beuvry, Beuvry, France, ¹⁶Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ¹⁷Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, ¹⁸Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁹Rheumatology, Private Practice, Valenciennes, Valenciennes, France, ²⁰CHU de Poitiers, Rheumatology, Poitiers, France, ²¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²²Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ²³Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²⁴Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ²⁵Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ²⁶University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France
Background/Purpose: Secukinumab (SEC) is an interleukin-17 inhibitor used to treat patients with axial spondylarthritis (axSpA) and psoriatic arthritis (PsA). Drug survival is often used as…
Abstract Number: 1494 • 2019 ACR/ARP Annual Meeting
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Joseph Merola¹, Shu Li ², Ming-Chun Hsu ², Chetan Karyekar ³, Susan Flavin ², Bruce Randazzo ⁴ and Laura Coates ⁵, ¹Brigham and Women's Hospital, Harvard Med School, Boston, MA, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to…
Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting
A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Tien Nguyen¹, Melvin Churchill ², Robert Levin ³, Guillermo Valenzuela ⁴, Joseph Merola ⁵, Alexis Ogdie ⁶, Ana-Maria Orbai ⁷, Jose Scher ⁸, Arthur Kavanaugh ⁹, Shital Agawane ¹⁰, Farid Kianifard ¹¹, Chauncy Rollins ¹¹ and Olivier Chambenoit ¹¹, ¹Department of Dermatology, University of California, Irvine, Irvine, CA, ²Arthritis Center of Nebraska, Lincoln, NE, ³Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁹University of California, San Diego School of Medicine, La Jolla, CA, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…
Abstract Number: 1553 • 2019 ACR/ARP Annual Meeting
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Philip Mease¹, Atul Deodhar ², Renato Calheiros ³, Xiangyi Meng ³, Todd Fox ⁴ and Xenofon Baraliakos ⁵, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: AS is a chronic, inflammatory disease of the axial skeleton associated with pain, stiffness, disability, and reduced quality of life (QOL).1 AS is defined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].